Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 5 (May)

1. Chronic myeloid leukemia blast crisis arises from progenitors.
   Stem Cells, 25(5): 1114-8. [Abstract] [Full-text]
2. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
   Eur Respir J, 29(5): 976-85. [Abstract] [Full-text]
3. We should desist using RECIST, at least in GIST.
   J Clin Oncol, 25(13): 1760-4. [Abstract] [Full-text]
4. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
   J Clin Oncol, 25(13): 1753-9. [Abstract] [Full-text]
5. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
   J Natl Cancer Inst, 99(9): 680-93. [Abstract] [Full-text]
6. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
   Oncologist, 12(4): 438-42. [Abstract] [Full-text]
7. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
   Clin Cancer Res, 13(9): 2643-50. [Abstract] [Full-text]
8. Over-expression of c-kit in a primary leiomyosarcoma of the thyroid gland.
   Eur Arch Otorhinolaryngol, 264(6): 705-8. [Abstract] [Full-text]
9. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
   Cancer, 109(10): 2068-76. [Abstract] [Full-text]
10. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.
    Cancer Lett, 251(2): 323-9. [Abstract] [Full-text]
11. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium.
    Blood, 109(10): 4264-71. [Abstract] [Full-text]
12. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
    Blood, 109(10): 4399-405. [Abstract] [Full-text]
13. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Blood, 109(10): 4143-50. [Abstract] [Full-text]
14. Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors.
    Genes Chromosomes Cancer, 46(6): 564-76. [Abstract] [Full-text]
15. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Trends Pharmacol Sci, 28(5): 197-9. [Abstract] [Full-text]
16. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.
    Cancer Res, 67(9): 4491-8. [Abstract] [Full-text]
17. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
    Cancer Res, 67(9): 4028-33. [Abstract] [Full-text]
18. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
    Blood, 109(7): 2791-3. [Abstract] [Full-text]
19. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Blood, 109(7): 3031-41. [Abstract] [Full-text]
20. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
    Br J Haematol, 137(5): 461-7. [Abstract] [Full-text]
21. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
    Br J Haematol, 137(5): 423-8. [Abstract] [Full-text]
22. Challenges for patient selection with VEGF inhibitors.
    Cancer Chemother Pharmacol, 60(2): 151-70. [Abstract] [Full-text]
23. Targeted therapies for soft-tissue sarcomas.
    Expert Rev Anticancer Ther, 7(5): 725-33. [Abstract] [Full-text]
24. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Oncogene, 26(21): 2975-87. [Abstract] [Full-text]
25. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
    Cancer, 109(8): 1556-60. [Abstract] [Full-text]
26. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Cancer, 109(8): 1543-9. [Abstract] [Full-text]
27. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
    Immunol Rev, 217: 38-52. [Abstract] [Full-text]
28. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
    J Pharmacol Exp Ther, 321(3): 856-65. [Abstract] [Full-text]
29. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Cancer Lett, 252(1): 75-85. [Abstract] [Full-text]
30. Therapeutic targets in chronic myeloid leukaemia.
    Hematol Oncol, 25(2): 66-75. [Abstract] [Full-text]
31. Gastrointestinal stromal tumour.
    Lancet, 369(9574): 1731-41. [Abstract] [Full-text]
32. Studies in target-based treatment.
    Mol Cancer Ther, 6(5): 1477. [Abstract] [Full-text]
33. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Leukemia, 21(6): 1183-8. [Abstract] [Full-text]
34. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
    Leukemia, 21(6): 1267-75. [Abstract] [Full-text]
35. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.
    Blood, 109(11): 5011-5. [Abstract] [Full-text]
36. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
    Blood, 109(11): 4635-40. [Abstract] [Full-text]
37. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
    Cancer, 109(9): 1897-904. [Abstract] [Full-text]
38. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Int J Cancer, 121(2): 257-64. [Abstract] [Full-text]
39. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
    Oncogene, 26(24): 3462-72. [Abstract] [Full-text]
40. Current and emerging treatment options in chronic myeloid leukemia.
    Cancer, 109(11): 2171-81. [Abstract] [Full-text]
41. Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs.
    Xenobiotica, 37(5): 503-13. [Abstract] [Full-text]
42. Pulmonary arterial hypertension: current therapeutic strategies.
    Nat Clin Pract Cardiovasc Med, 4(6): 319-29. [Abstract] [Full-text]
43. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.
    Arterioscler Thromb Vasc Biol, 27(6): 1456-62. [Abstract] [Full-text]
44. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
    Oncogene, 26(24): 3482-91. [Abstract] [Full-text]
45. GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription.
    Mol Cell Biol, 27(12): 4261-72. [Abstract] [Full-text]
46. Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103(6): e44-8. [Abstract] [Full-text]
47. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.
    Cell Prolif, 40(3): 355-66. [Abstract] [Full-text]
48. Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate.
    J Gastroenterol, 42(5): 402-5. [Abstract] [Full-text]
49. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).
    Br J Cancer, 96(11): 1656-8. [Abstract] [Full-text]
50. Imatinib effect on growth and signal transduction in polycythemia vera.
    Exp Hematol, 35(6): 931-8. [Abstract] [Full-text]
51. A rapid assay for drug sensitivity of glioblastoma stem cells.
    Biochem Biophys Res Commun, 358(3): 908-13. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.